Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Employees - 110,
CEO - Dr. Kevin Koch Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 1.29B
Altman ZScore(max is 10): 26.94, Piotroski Score(max is 10): 2, Working Capital: $451623000, Total Assets: $486817000, Retained Earnings: $-378576000, EBIT: -158832000, Total Liabilities: $27601000, Revenue: $0
AryaFin Target Price - $0.39 - Current Price $13.58 - Analyst Target Price $41.22
| Ticker | EWTX |
| Index | RUT |
| Curent Price | 13.58 |
| Change | -12.50% |
| Market Cap | 1.29B |
| Average Volume | 1.43M |
| Income | -133.81M |
| Sales | 0.00M |
| Book Value/Share | 4.84 |
| Cash/Share | 4.94 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 110 |
| Moving Avg 20days | -42.27% |
| Moving Avg 50days | -46.89% |
| Moving Avg 200days | -46.63% |
| Shares Outstanding | 94.84M |
| Earnings Date | Mar 03 BMO |
| Inst. Ownership | 78.77% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 2.80 |
| Price/Cash | 2.75 |
| Price/FCF | - |
| Quick Ratio | 19.93 |
| Current Ratio | 19.93 |
| Debt/Equity | 0.01 |
| Return on Assets | -32.37% |
| Return on Equity | -34.40% |
| Return on Investment | -28.90% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 17.59 |
| BETA(β) | 0.32 |
| From 52week Low | 11.49% |
| From 52week High | -64.38% |
| EPS | -1.45 |
| EPS next Year | -2.05 |
| EPS next Qtr | -0.43 |
| EPS this Year | -28.55% |
| EPS next 5 Year | -12.71% |
| EPS past 5 Year | -49.00% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | 7.97% |
| Sales Y/Y | - |
| EPS Q/Q | 10.03% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | -0.67% |
| ATR(14) | 2.47 |
| Perf Week | -42.06% |
| Perf Month | -49.16% |
| Perf Quarter | -49.14% |
| Perf Year | -23.15% |
| Perf YTD | -49.14% |
| Target Price | 41.22 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer